Peptide-based drug discovery & development

Pharmaceutical Outsourcing

Volumn 15, Issue 2, 2014, Pages

  Otvos, Laszlo ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

MINOR HISTOCOMPATIBILITY ANTIGEN; PEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT;

ARTICLE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; IMMUNE RESPONSE; KIDNEY CLEARANCE; NONHUMAN; PROCESS DEVELOPMENT; T LYMPHOCYTE; THERAPEUTIC MISCONCEPTION; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84897985129     PISSN: 19453337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Goodwin, D. Simerska, P. Toth, I. (2012) Peptides as therapeutics with enhanced bioactivity. Curr. Med. Chem. 19, 4451-4461.
2. Meydan, C. Out, H.H. Sezerman, O.U. (2013) Prediction of peptides binding to MHC class I and class II alleles by temporal motif mining. BMC Bioinform. 14, S13.
3. Herve, M. Maillere, B. Mourier, G. et al. (1997) On the immunogenic properties of retro-inverso peptides. Total retro-inversion of T-cell epitopes causes a loss of binding to MHC II molecules. Mol. Immunol. 34, 157-163.
4. Hancock, D.C. O'Reilly, N.J. (2005) Synthetic peptides as antigens for antibody production. Meth. Mol. Biol. 295 (Immunochemical Protocols), 13-25.
5. Zheng, W. Azzopardi, K. Hocking, D. et al. (2012) A totally synthetic lipopeptide-based self-adjuvanting vaccine induces neutralizing antibodies against heat-stable enterotoxin from enterotoxigenic Esherichia coli. Vaccine 30, 4800-4806.
6. Lozano, J.M. Lesmes, L.P. Careno, L.F. et al. (2010) Development of designed site-directed pseudopeptide-peptidomimetic immunogens as novel minimal subunit vaccine candidates for malaria. Molecules 15, 8856-8889.
7. Noto, P.B. Abbadessa, G. Cassone, M. et al. (2008) Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo. Protein Sci. 17, 1249-1255.
8. Wolf, A.I. Mozdzanowska, K. Williams, K.L. et al. (2011) Vaccination with M2e-based multiple antigenic peptides: characterization of the B cell response and protection efficacy in inbred and outbred mice. PloS One 6, e28445.
9. Powell, M.F. Grey, H. Gaeta, F. et al. (1992) Peptide stability in drug development: a comparison of peptide reactivity in different biological media. J. Pharm. Sci. 81, 731-735.
10. Powell, M.F. Stewart, T. Otvos, L. Jr. et al. (1993) Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum. Pharmacol. Res. 10, 1268-1273.
11. Otvos, L. Jr. Surmacz, E. (2011) Targeting the leptin receptor: a potential new mode of treatment for breast cancer. Expert Rev. Anticancer Ther. 11, 1147-1150.
12. Beccari, S. Kovalszky, I. Wade, J.D. et al. (2013) Designer peptide antagonist of the leptin receptor with peripheral antineoplastic activity. Peptides 44, 127-134.
13. Otvos, L. Jr. Kovalszky, I. Scolaro, L. et al. (2011) Peptide-based leptin receptor antagonists for cancer treatment and appetite regulation. Biopolymers 96, 117-125.
14. Janssen, S. Rosen, D.M. Ricklis, R.M. et al. (2006) Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandural kallikrenin 2 (hK2)-activated thapsigargin prodrug. The Prostate 66, 358-368.
15. Sakamoto, H. Hatano, K. Higashi,Y. et al. (1993) Animal pharmacokinetics of FK037, a novel parenteral broad-spectrum cephalosporin. J. Antibiot. 46, 120-130.
16. Atkinson, T. (2002) Lifestyle drug market booming. Nat. Med. 8, 909.
17. Gupta, V. Hwang, B.H. Lee, J. et al. (2013) Mucoadhesive intestinal devices for oral delivery of salmon calcitonin. J. Controlled Rel. 172, 753-762.
18. Sachdeva, V. Zhou, Y. Banga, A.K. (2013) In vivo transdermal delivery of leuprolide using microneedles and iontophoresis. Curr. Pharm. Biotechnol. 14, 180-193.
19. Wang, S. Wu, M. Li, D. et al. (2012) preparation, characterization and related in vivo release, safety and toxicity studies of long acting lanreotide microspheres. Biol. Pharm. Bull. 35, 1898-1906.
20. Maggio, E.T. (2006) Intravail: highly effective intranasal delivery of peptide and protein drugs. Expert Opin. Drug Deliv. 3, 529-539.
21. Lugaresi, A. (2013) RebiSmart TM (version 1.5) device for multiple sclerosis treatment delivery and adherence. Expert Opin. Drug Deliv. 10, 273-283.